A phase Ia trial of SEL-212 for treatment of refractory and tophaceous gout and tumor lysis syndrome
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2016
At a glance
- Drugs SEL 212 (Primary)
- Indications Gout; Tumour lysis syndrome
- Focus Adverse reactions; Proof of concept
- Sponsors Selecta Biosciences
- 07 Dec 2016 Results published in the Selecta Biosciences Media Release
- 07 Dec 2016 According to a Selecta Biosciences media release, all patient visits has been completed in this and other Phase I trial (266205).
- 26 Oct 2016 Results from this and another phase I trial will be presented at the 11th Annual Immunization and Vaccine Summit (IMVACS) 2016, according to a Selecta Biosciences media release.